Hjorth-Hansen, H
Stentoft, J
Richter, J
Koskenvesa, P
Höglund, M
Dreimane, A
Porkka, K
Gedde-Dahl, T
Gjertsen, B T
Gruber, F X
Stenke, L
Eriksson, K M
Markevärn, B
Lübking, A
Vestergaard, H
Udby, L
Bjerrum, O W
Persson, I
Mustjoki, S
Olsson-Strömberg, U
,
Article History
Received: 3 March 2016
Revised: 5 April 2016
Accepted: 8 April 2016
First Online: 2 May 2016
Competing interests
: The Nordic CML Study group is an open academic forum for research on CML, and has performed clinical studies and received financing for this in collaborations with BMS, Novartis, Pfizer and MSD. The present study was supported by MSD and BMS by provision of study drug free of charge and BMS gave financial support for study administration. Individual investigators have the following ties to declare: Henrik Hjorth-Hansen: ARIAD and BMS (consulting); Jesper Stentoft: Novartis, BMS, Pfizer, ARIAD (study support); Johan Richter: ARIAD, BMS and Novartis (consulting); Perttu Koskenvesa: ARIAD (consulting); Martin Höglund: Akinion Oharmaceuticals (consulting) and Janssen-Cilag (temporary advisory board); Kimmo Porkka: Novartis, BMS and Pfizer honoraria (advisory board or speaker) and research funding; Bjørn Tore Gjertsen: ARIAD, Bayer, BerGenBio, Pfizer, MedImmune, Novartis and Roche (consulting and advisory boards). Stock equity owner: Kin<i>N</i> Therapeutics and ACT2, Ole Weis Bjerrum: BMS, Novartis, Ariad and Pfizer; Satu Mustjoki: Novartis, BMS and Pfizer honoraria (advisory board or speaker) and Ariad research funding; Ulla Olsson-Strömberg: ARIAD (honoraria). The other authors declare no conflict of interest.